| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
BRIEF REPORT |
Hospital for Children and Adolescents (A.M.W., M.H., L.D.), Helsinki University Central Hospital, University of Helsinki, FI-00029 Helsinki, Finland; University Department of Growth and Reproduction (K.B., A.-M.A.), Rigshospitalet, DK-2100 Copenhagen, Denmark; and Department of Pediatrics (L.D.), Kuopio University Hospital, University of Kuopio, FI-70211 Kuopio, Finland
Address all correspondence and requests for reprints to: Anne Wikström, M.D., Helsinki University Central Hospital, Hospital for Children and Adolescents, P.O. Box 281, FI-00029 Helsinki, Finland. E-mail: anne.wikstrom{at}fimnet.fi.
| Abstract |
|---|
|
|
|---|
Objective: The objective of the study was to characterize changes in INSL3 levels during spontaneous puberty in healthy boys, boys with aromatase inhibitor-induced hypergonadotropic hyperandrogenism, and boys with Leydig cell dysfunction.
Design: This was a prospective clinical study.
Setting: The study was conducted at a university hospital pediatric endocrinology outpatient clinic.
Patients: Patients included 30 healthy boys with idiopathic short stature (ISS) aged 9.014.5 yr and 14 boys with Klinefelter syndrome (KS) aged 1013.9 yr.
Intervention: In ISS boys, intervention included aromatase inhibitor letrozole or placebo for 24 months.
Main Outcome Measures: Serum INSL3 levels in relation to bone age, Tanner pubertal stages, and LH and testosterone levels were measured.
Results: Onset of puberty was associated with a significant increase in INSL3 levels from 0.06 ± 0.01 ng/ml at Tanner G1 to 0.32 ± 0.16 ng/ml at G2 (P < 0.0001). Adult INSL3 levels (
0.55 ng/ml) were attained at bone age 1314 yr. ISS boys with letrozole-induced hypergonadotropic hyperandrogenism had, after 12 months of therapy, higher INSL3 levels than did placebo treated (0.85 ± 0.54 vs. 0.26 ± 0.17 ng/ml, P < 0.01). In KS boys during spontaneous puberty, after an initial increase similar to that in healthy boys, INSL3 concentrations leveled off despite hyperstimulation by LH. Positive correlations occurred between serum INSL3 and LH and between INSL3 and testosterone levels in all three groups (P < 0.0001).
Conclusions: In boys, the Leydig cell-specific hormone INSL3 may serve as a new marker for onset and progression of puberty. Pubertal increase in INSL3 levels seems to depend on LH. In KS subjects, INSL3 concentrations indicate Leydig cell dysfunction from midpuberty onward.
| Introduction |
|---|
|
|
|---|
Recently serum INSL3 levels have been measured in normal men and men with different testicular pathologies (3, 4). These studies have shown that circulating INSL3 is entirely of testicular origin and that the concentrations of this hormone seem to reflect the functional status of the Leydig cells (3, 4). For example, adult patients with Klinefelter syndrome (KS) have significantly below normal INSL3 concentrations (3, 4). Production of both INSL3 and testosterone (T) is related to LH (3, 4), but recent data strongly suggest that the production of these hormones is regulated differently because INSL3 secretion is probably dependent on the long-term trophic effect of LH on Leydig cell differentiation (4).
The aim of this study was to characterize the changes in INSL3 levels during normal puberty by means of a newly developed time-resolved fluorescence immunoassay (4). Furthermore, we also studied the role of gonadotropins in the regulation of INSL3 secretion during puberty in two different models: aromatase inhibitor-treated boys with drug-induced hypergonadotropic hyperandrogenism and boys with KS who developed hypergonadotropism due to Leydig cell dysfunction.
| Subjects and Methods |
|---|
|
|
|---|
Thirty healthy boys aged 9.014.5 yr were enrolled in a study on idiopathic short stature (ISS) at the outpatient clinic for pediatric endocrinology of the Hospital for Children and Adolescents, Helsinki University Central Hospital. Our selection of patients and study protocol have been described in detail previously (5). These boys were randomized to receive either the aromatase inhibitor letrozole (Lz; Femar, Novartis AG, Basel, Switzerland) at a dose of 2.5 mg or placebo (Pl) orally once daily for 2 yr. During the treatment, the boys were examined every 6 months and again 12 months after the cessation of treatment.
Boys with KS
Fourteen nonmosaic 47,XXY boys aged 10.013.9 yr were followed up at the same university clinic every 46 months. Some of the resultant clinical and hormonal data have already appeared (6, 7). None of the subjects were or had been on androgen therapy.
The parents of each boy gave their informed consent for participation in these studies, which had been approved by the research ethics committee of the Hospital District of Helsinki and Uusimaa.
Clinical follow-up
In both groups, at each visit, stage of puberty was evaluated according to Tanner (8), and venous blood samples were drawn for biochemical measurements. Bone ages assessed by the method of Greulich and Pyle (9) rather than chronological ages were used because the majority of the ISS boys had delayed bone age.
Biochemical measurements
INSL3 serum concentrations were analyzed by a semicompetitive time-resolved fluorescence immunoassay specific for human INSL3. This assay has a detection limit of 0.05 ng/ml, and intra- and interassays coefficients of variations of 8.0 and 11.3%. For further details, see Bay et al. (4). Serum LH, T, and inhibin B levels determinations were by methods previously described (5, 6, 7).
Statistical analyses
Values, unless otherwise stated, are expressed as mean ± SD. To reduce frequency bias, means were calculated to obtain for each subject one value for each age or puberty stage interval. Comparisons between the Pl-treated ISS and KS groups and within these groups were by unpaired two-tailed Students t test. Differences between the Lz- and Pl-treated ISS boys were analyzed by repeated-measures ANOVA. Relations between INSL3 and other hormones were tested by linear regression analysis. P < 0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
Onset of puberty was associated with a marked increase in INSL3 levels (from Tanner pubertal stage 1 to 2) that occurred concomitantly with significant increases in T and LH levels (Table 1
). Significant increases in serum INSL3 and LH levels took place between bone ages 1011 yr and 1112 yr, and adult INSL3 concentrations 0.55 ng/ml or greater (4) were reached at bone age 1314 yr (Table 1
).
|
The nine boys who entered puberty within 18 months from the start of Lz therapy showed a marked increase in serum INSL3 levels from 0.21 ± 0.19 ng/ml (month 0) to 1.15 ± 0.55 ng/ml (24 months), whereas the eight Pl-treated ISS boys, who entered puberty during follow-up, showed an increase from 0.08 ± 0.06 ng/ml (month 0) to 0.53 ± 0.14 ng/ml (24 months) (Fig. 1
). One year after cessation of Lz therapy, a slight decrease in INSL3 levels was noted to 1.00 ± 0.36 ng/ml (Fig. 1
).
|
In KS boys in comparison with healthy boys, no significant difference in INSL3 levels emerged in assessment according to bone age or Tanner pubertal stages (Table 1
). In the KS boys, the increase in serum INSL3 was significant between bone ages 1112 and 1213 yr and from Tanner pubertal stage P1 to P2 (Table 1
). Adult INSL3 levels (
0.55 ng/ml) (4) were reached at bone age 1213 yr. Thereafter INSL3 and T concentrations leveled off despite increasing LH levels (Table 1
).
After this study, two of the KS boys were started on T substitution therapy. After 6 months on T (Sustanon 250; Organon, Oss, The Netherlands), 1 mg/kg every fourth week, their serum INSL3 decreased from 0.68 to 0.11 ng/ml and from 0.49 to 0.04 ng/ml. At the same time, their serum LH levels decreased from 21.3 to 4.1 IU/liter and from 17.0 to 1.4 IU/liter.
Correlations of INSL3 levels with testicular volume and serum LH, T, and inhibin B levels
Significant correlations (|r| = 0.600.90, P < 0.0001) appeared in all three patient groups between INSL3 and testicular volume, LH, T, and inhibin B concentrations. No differences in INSL3/testicular volume and INSL3/LH correlations appeared between the Pl- and Lz-treated ISS groups. The Lz-treated had significantly lower INSL3 to T ratios (P < 0.05) and furthermore, significantly higher INSL3/inhibin B ratios (P < 0.001) than did the Pl treated.
Because testicular volumes in the KS boys never exceeded 4.5 ml, the KS boys displayed higher INSL3 to testicular volume ratios than did ISS boys (P < 0.0001). The KS boys displayed low INSL3 levels when the hypergonadotropism with high LH levels occurred; this difference in INSL3 to LH ratios from those of the healthy boys was significant (P < 0.0001). In INSL3/T correlations, the differences between these two groups were nonsignificant (P = 0.07). Furthermore, the KS boys showed an inverse correlation between INSL3 and inhibin B (r = 0.63, P < 0.0001) because secretion of inhibin B was very rapidly suppressed after onset of puberty.
| Discussion |
|---|
|
|
|---|
Studies have suggested that LH regulates INSL3 and T secretion differently. T secretion is more acutely sensitive to LH, whereas INSL3 secretion is more dependent on the trophic effect on Leydig cell differentiation (3, 4, 10). The dependence of INSL3 secretion on LH was verified in this study because, concomitantly with pubertal activation of LH secretion, INSL3 concentrations began to rise. Furthermore, the boys treated with the aromatase inhibitor Lz developed hypergonadotropic hyperandrogenism (5) and had significantly higher INSL3 levels than did Pl-treated boys.
Secretion of the Sertoli cell hormone inhibin B increases significantly at onset of puberty, but thereafter serum levels remain relatively constant (11, 12). Inhibin B concentrations are regulated by FSH, and during puberty an inverse relationship develops between FSH and inhibin B (11, 13). Although both FSH and LH rose significantly during Lz treatment, throughout the treatment period, only INSL3 levels showed a marked increase, not inhibin B levels (5). Thus, contrary to the inverse relationship between FSH and inhibin B, the positive relationship between LH and INSL3 was sustained in healthy boys throughout puberty. Furthermore, in the two KS boys started on T substitution, LH as well as INSL3 levels decreased markedly, verifying the dependence of INSL3 on LH stimulation during puberty. The gene for the INSL3 receptor LGR8 is expressed in the pituitary (14), but neither the present study nor previous studies (3, 4, 10) have shown a negative feedback regulation by INSL3 on LH secretion.
In KS boys, after an initial rise in serum INSL3 concentrations at onset of puberty, a tendency for a leveling off in the concentrations occurred despite stimulation by increasing LH levels. This is consistent with the histological findings in our earlier study (6); at onset of puberty, as the juvenile Leydig cells were transformed to adult type cells, they also gradually became hypertrophic. However, whereas Leydig cell function after onset of puberty remains within the low normal range as indicated by INSL3 and T levels, inhibin B secretion decreases very rapidly (6, 7, 15), reflecting the rapid degeneration of the seminiferous tubules.
Earlier studies have suggested that INSL3 is more sensitive than T to Leydig cell dysfunction (3, 4, 10). Actually we have shown that during puberty, T levels in KS boys did not differ from those in healthy boys during puberty (7). In that study we concluded that KS boys do not require androgen substitution until midpuberty, when other subtle signs of androgen deficiency become evident (7). Our observations in the present study on INSL3 concentrations in these KS boys support that finding.
In conclusion, our study shows that serum INSL3 concentrations may serve as novel markers for onset and normal progression of puberty. Secretion of INSL3 was dependent on LH, and during pubertal development, there existed a strong positive correlation with serum LH and T levels as well as testicular volume. In KS subjects, INSL3 measurements also indicate impaired Leydig cell function from midpuberty onward.
| Footnotes |
|---|
Disclosure summary: Authors A.M.W., K.B., M.H., A.-M.A., and L.D. have nothing to declare.
First Published Online August 22, 2006
Abbreviations: INSL3, Insulin-like factor 3; ISS, idiopathic short stature; KS, Klinefelter syndrome; Lz, letrozole; Pl, placebo; T, testosterone.
Received March 27, 2006.
Accepted August 14, 2006.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. Ivell and R. Anand-Ivell Biology of insulin-like factor 3 in human reproduction Hum. Reprod. Update, July 1, 2009; 15(4): 463 - 476. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Lague and J. J. Tremblay Antagonistic Effects of Testosterone and the Endocrine Disruptor Mono-(2-Ethylhexyl) Phthalate on INSL3 Transcription in Leydig Cells Endocrinology, September 1, 2008; 149(9): 4688 - 4694. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Foresta, D. Zuccarello, A. Garolla, and A. Ferlin Role of Hormones, Genes, and Environment in Human Cryptorchidism Endocr. Rev., August 1, 2008; 29(5): 560 - 580. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Anand-Ivell, R. Ivell, D. Driscoll, and J. Manson Insulin-like factor 3 levels in amniotic fluid of human male fetuses Hum. Reprod., May 1, 2008; 23(5): 1180 - 1186. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Bay, H. E. Virtanen, S. Hartung, R. Ivell, K. M. Main, N. E. Skakkebaek, A.-M. Andersson, The Nordic Cryptorchidism Study Group, and J. Toppari Insulin-Like Factor 3 Levels in Cord Blood and Serum from Children: Effects of Age, Postnatal Hypothalamic-Pituitary-Gonadal Axis Activation, and Cryptorchidism J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 4020 - 4027. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Wikstrom, C. E. Hoei-Hansen, L. Dunkel, and E. Rajpert-De Meyts Immunoexpression of Androgen Receptor and Nine Markers of Maturation in the Testes of Adolescent Boys with Klinefelter Syndrome: Evidence for Degeneration of Germ Cells at the Onset of Meiosis J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 714 - 719. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |